Logo image of TOVX

THERIVA BIOLOGICS INC (TOVX) Stock Fundamental Analysis

NYSEARCA:TOVX - American Stock Exchange - US87164U5083 - Common Stock

1.51  +0.03 (+2.03%)

After market: 1.32 -0.19 (-12.58%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TOVX. TOVX was compared to 572 industry peers in the Biotechnology industry. TOVX may be in some trouble as it scores bad on both profitability and health. TOVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TOVX had negative earnings in the past year.
In the past year TOVX has reported a negative cash flow from operations.
TOVX had negative earnings in each of the past 5 years.
In the past 5 years TOVX always reported negative operating cash flow.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -66.55%, TOVX is doing worse than 63.89% of the companies in the same industry.
TOVX has a Return On Equity of -108.35%. This is comparable to the rest of the industry: TOVX outperforms 43.54% of its industry peers.
Industry RankSector Rank
ROA -66.55%
ROE -108.35%
ROIC N/A
ROA(3y)-31.35%
ROA(5y)-67.33%
ROE(3y)-39.46%
ROE(5y)-77.34%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TOVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

TOVX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TOVX has been increased compared to 5 years ago.
Compared to 1 year ago, TOVX has a worse debt to assets ratio.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -12.75, we must say that TOVX is in the distress zone and has some risk of bankruptcy.
TOVX has a worse Altman-Z score (-12.75) than 80.00% of its industry peers.
TOVX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TOVX (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.75
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.67 indicates that TOVX has no problem at all paying its short term obligations.
With a Current ratio value of 2.67, TOVX is not doing good in the industry: 69.91% of the companies in the same industry are doing better.
A Quick Ratio of 2.67 indicates that TOVX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.67, TOVX is not doing good in the industry: 68.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.67
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.87% over the past year.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.43% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.59%
EPS Next 2Y16.4%
EPS Next 3Y13.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1K -2K -3K -4K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

TOVX's earnings are expected to grow with 13.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y13.43%

More info and screens

0

5. Dividend

5.1 Amount

TOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (1/21/2025, 8:04:00 PM)

After market: 1.32 -0.19 (-12.58%)

1.51

+0.03 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners20.95%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap4.20M
Analysts82.5
Price Target6.12 (305.3%)
Short Float %10.77%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2093.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-29.25
EYN/A
EPS(NY)-18.87
Fwd EYN/A
FCF(TTM)-6.78
FCFYN/A
OCF(TTM)-6.76
OCFYN/A
SpS0
BVpS8.86
TBVpS8.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.55%
ROE -108.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.35%
ROA(5y)-67.33%
ROE(3y)-39.46%
ROE(5y)-77.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.67
Altman-Z -12.75
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)98.02%
Cap/Depr(5y)59.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.37%
EPS Next Y7.59%
EPS Next 2Y16.4%
EPS Next 3Y13.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.45%
OCF growth 3YN/A
OCF growth 5YN/A